Abivax (ABVX) Cash from Financing Activities (2024 - 2026)

Abivax's Cash from Financing Activities history runs 3 years deep, the most recent figure standing at $85464.4 for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 101.04% year-over-year to $85464.4 in Q1 2026; TTM through Mar 2026 was $649.6 million, a 82091.53% increase from a year earlier, with the FY2025 full-year figure at $637.1 million, up 1987.29% from the prior year.
• Cash from Financing Activities rose to $85464.4 in Q1 2026 per ABVX's latest filing, from -$46.0 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $705.5 million in Q3 2025 and bottomed at -$46.0 million in Q4 2025.
• The 3-year median for Cash from Financing Activities is -$6.2 million (2024), against an average of $74.6 million.
• Biggest YoY gain for Cash from Financing Activities was 10314.41% in 2025; the steepest drop was 638.73% in 2025.
• Year by year, Cash from Financing Activities stood at -$6.2 million in 2024, then slumped by 638.73% to -$46.0 million in 2025, then surged by 100.19% to $85464.4 in 2026.
• Per Business Quant, the three latest ABVX Cash from Financing Activities figures stand at $85464.4 (Q1 2026), -$46.0 million (Q4 2025), and $705.5 million (Q3 2025).